Comparing the Safety and Effectiveness of Anrikefon and Nalbuphine for Pain Relief After Eye Surgery in Adults Aged 18 to 70

What this Trial Is About

Researchers are evaluating whether Anrikefon works as well as nalbuphine to manage pain after ophthalmic surgery in adults under general anesthesia. This clinical trial focuses on comparing the pain relief, side effects like sedation or dizziness, and recovery speed between Anrikefon and nalbuphine. The goal is to see if Anrikefon can provide effective and safer pain control for patients undergoing eye surgery as day procedures. Participants will receive an intravenous dose of either Anrikefon at 1 microgram per kilogram or nalbuphine at 0.1 milligram per kilogram, given 15 minutes before the end of surgery. The study is randomized and includes two groups one receiving Anrikefon and the other nalbuphine. Both treatments will be carefully monitored throughout the surgery and recovery periods. During the study, participants pain levels will be measured at rest and during eye movement using a numeric scale at various times up to one month after surgery. Other assessments include the need for additional pain medications, recovery quality, hospital stay length, and eye health measures such as intraocular pressure and visual acuity. Safety and side effects will be tracked closely, with follow-up visits scheduled up to one month postoperatively. The total study participation covers surgery and subsequent recovery monitoring.

Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery